Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.51 (¥3,470)+0.93%▲ (in JPY terms)
SoftBank|$33.62 (¥5,424)-9.01%▼ (in JPY terms)
MUFG|$21.53 (¥3,473)-4.30%▼ (in JPY terms)
Keyence|$439.33 (¥70,880)-4.28%▼ (in JPY terms)
Nintendo|$45.21 (¥7,294)+3.02%▲ (in JPY terms)
NTT|$0.94 (¥151)+0.13%▲ (in JPY terms)
Takeda|$33.97 (¥5,480)+2.53%▲ (in JPY terms)
Tokyo Electron|$403.50 (¥65,100)-8.17%▼ (in JPY terms)
Recruit|$79.46 (¥12,820)+1.63%▲ (in JPY terms)
ITOCHU|$11.79 (¥1,903)-0.89%▼ (in JPY terms)
Honda|$9.52 (¥1,536)-1.48%▼ (in JPY terms)
Shin-Etsu|$44.36 (¥7,157)-2.77%▼ (in JPY terms)
Tokio Marine|$46.65 (¥7,526)-0.97%▼ (in JPY terms)
Fast Retailing|$488.67 (¥78,840)+0.00%▲ (in JPY terms)
Toyota|$17.53 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$21.51 (¥3,470)+0.93%▲ (in JPY terms)
SoftBank|$33.62 (¥5,424)-9.01%▼ (in JPY terms)
MUFG|$21.53 (¥3,473)-4.30%▼ (in JPY terms)
Keyence|$439.33 (¥70,880)-4.28%▼ (in JPY terms)
Nintendo|$45.21 (¥7,294)+3.02%▲ (in JPY terms)
NTT|$0.94 (¥151)+0.13%▲ (in JPY terms)
Takeda|$33.97 (¥5,480)+2.53%▲ (in JPY terms)
Tokyo Electron|$403.50 (¥65,100)-8.17%▼ (in JPY terms)
Recruit|$79.46 (¥12,820)+1.63%▲ (in JPY terms)
ITOCHU|$11.79 (¥1,903)-0.89%▼ (in JPY terms)
Honda|$9.52 (¥1,536)-1.48%▼ (in JPY terms)
Shin-Etsu|$44.36 (¥7,157)-2.77%▼ (in JPY terms)
Tokio Marine|$46.65 (¥7,526)-0.97%▼ (in JPY terms)
Fast Retailing|$488.67 (¥78,840)+0.00%▲ (in JPY terms)

Eisai Co.,Ltd.

2026-07-15 Eisai Co.,Ltd. “The results of the "Rekenbi®" real-world clinical LEADER study were presented at AAIC 2026—among patients with early-stage Alzheimer's disease who received treatment for an average of 17 months, over 75% maintained their disease stage and approximately 7% showed improvement—these real-world clinical data support the long-term benefits of continued administration of "Rekenbi" and provide important insights into the actual treatment practices in daily clinical practice.”

by

2026-07-15 Eisai Co.,Ltd. “The results of the "Rekenbi®" real-world clinical LEADER study were … 続きを読む

2026-07-14 Eisai Co.,Ltd. “New findings on Etalanetug (E2814) will be presented at AAIC 2026 – Etalanetug reduces eMTBR-tau243, a blood biomarker specific to tau aggregates in Alzheimer's disease – Measuring the blood biomarker eMTBR-tau243 may be a practical and minimally invasive method for capturing pathological changes specific to Alzheimer's disease, and is expected to play an important role in the future clinical development of etalanetug.”

by

2026-07-14 Eisai Co.,Ltd. “New findings on Etalanetug (E2814) will be presented at AAIC 2026 – Etalanetu … 続きを読む

2026-07-14 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody LEQEMBI®, has received approval from the U.S. FDA as an initial treatment for early-stage Alzheimer's disease. LEQEMBI IQLIK is the world's first and only anti-amyloid therapy that offers the convenience of home administration from initial treatment to maintenance therapy. LEQEMBI IQLIK is scheduled to be launched in the U.S. in late August 2026 as an initial treatment.”

by

2026-07-14 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody … 続きを読む

2026-07-13 Eisai Co.,Ltd. “Clinical data supporting the efficacy and safety of the "Rekenbi®" subcutaneous autoinjector, comparable to intravenous formulations, in early Alzheimer's disease were presented at AAIC 2026. New clinical and real-world data support a subcutaneous treatment pathway from initial therapy to ongoing therapy, contributing to improved convenience for patients and care partners.”

by

2026-07-13 Eisai Co.,Ltd. “Clinical data supporting the efficacy and safety of the "Rekenbi®" … 続きを読む

2026-06-15 Eisai Co.,Ltd. “With support from the UK government's Life Sciences Innovative Manufacturing Fund, we are making a strategic investment in our Hatfield UK facility—a strategic investment aimed at bringing in-house production and packaging systems for pharmaceuticals requiring temperature control.”

by

2026-06-15 Eisai Co.,Ltd. “With support from the UK government's Life Sciences Innovative Manufactur … 続きを読む

Contact